NVE Corporation (NVEC) - 10-K Summary
Business Context and Reporting Period
Company: NVE Corporation
Filing Type: Annual Report (Form 10-K)
Period Ended: March 31, 2010
Business Overview: NVE develops and sells spintronic devices (sensors, couplers) and licenses MRAM technology. The company operates in a single reportable segment, serving markets in factory automation, medical devices, and industrial control. International sales accounted for approximately 49% of total revenue.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 | Change |
|---|---|---|---|
| Total Revenue | $28,147,185 | $23,372,269 | +20.4% |
| Gross Profit | $19,834,170 | $16,648,027 | +19.1% |
| Gross Margin | 70.5% | 71.2% | -0.7 pts |
| Net Income | $11,999,344 | $9,782,895 | +22.7% |
| Diluted EPS | $2.47 | $2.04 | +21.1% |
| Operating Cash Flow | $12,463,616 | $9,998,114 | +24.7% |
| Cash & Marketable Securities | $49,543,766 | $34,321,811 | +44.4% |
| Total Debt | $0 | $0 | N/A |
Note: The company reported no long-term debt or capital lease obligations as of March 31, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% driven by a 15% rise in product sales and a 50% surge in contract research and development (R&D) revenue. Product sales growth was led by strong medical device component sales, offsetting weakness in industrial control markets.
- Margin Compression: Gross margin decreased slightly to 70.5% from 71.2% due to a higher mix of lower-margin contract R&D revenue.
- Expense Management: R&D expenses decreased 8% as resources were reallocated to billable contract R&D activities. Selling, general, and administrative (SG&A) expenses increased 11% primarily due to higher salaries and commissions.
- Interest Income: Interest and other income increased 38% to $1.62 million, driven by a larger portfolio of interest-bearing marketable securities.
- Backlog: Firm contract R&D backlog decreased to $1.53 million from $2.20 million in the prior year.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes working capital and cash generated from operations are adequate for needs through fiscal 2011. The company holds approximately $48.2 million in marketable securities (84% of total assets).
- Key Risks:
- Customer Concentration: Reliance on large customers (Avago, Phonak, St. Jude Medical, U.S. Government) for a significant percentage of revenue.
- Supply Chain: Dependence on single-source suppliers for critical wafers and packaging vendors (e.g., CEI in Thailand, which is under debt rehabilitation).
- MRAM Licensing: Future revenue depends on the adoption of MRAM technology by licensees; no assurance of new licensing agreements.
- Product Liability: Sensors used in medical devices expose the company to potential liability claims.
- Unusual Items: No material unusual items were reported. The company had no stock repurchases during the quarter ended March 31, 2010, though a $2.5 million authorization remains available.
Investor Verification Checklist
- Customer Concentration: Verify the status of agreements with top customers (Avago, St. Jude, Phonak) as several expire in 2010-2012.
- Supply Chain Resilience: Assess the risk associated with single-source packaging vendors, specifically the financial stability of Circuit Electronic Industries (CEI) in Thailand.
- Investment Portfolio Risk: Review the credit quality of the $48 million marketable securities portfolio, noting that while rated highly, some bonds held unrealized losses due to market fluctuations.
- R&D Sustainability: Evaluate the sustainability of the 50% increase in contract R&D revenue, as government and non-government contracts can fluctuate significantly.
- MRAM Strategy: Monitor progress on MRAM licensing deals, particularly the unresolved status of negotiations with Freescale/EverSpin regarding the Motorola patent license.